This site is intended for healthcare professionals only
LoginRegister
Language Row Costs Pharmacist: Action Ordered for Giving Wrong Medicine, Refusing BengaliOver 36 percent of inspected drug-making units had to be shut: CDSCO chief
Govt extends deadline for submitting applications under PLI SchemeBoosting local manufacturing: India plans incentives for diabetes, obesity drug makers in 2026
Shilpa Biologicals, Stein Cares Ink Exclusive Biosimilar Licensing Pact for Latin AmericaOrchid Pharma collaborates with Cipla to unveil antibiotic Cefepime-Enmetazobactam in India
Roche Drops Muscle Disease Drug After Trial FailureRoche Vabysmo gets CHMP recommendation for third indication retinal vein occlusion
Setback to Sun Pharma as Fibromun, Nidlegy Trials Miss Key Endpoints in Cancer StudiesSun Pharma Laboratories Gets CDSCO Panel Nod To study Antidiabetic FDC Drug
After 40 Years, USFDA Approves Vanda Pharmas Motion Sickness Drug NereusAlembic Pharma secures USFDA okay for Doxycycline Capsules for inflammatory lesions of rosacea
Novartis to Acquire Excellergy in USD 2 Billion Deal to Boost Food Allergy PipelineCDSCO Panel Approves Novartis Protocol Amendment Proposal To Study Ianalumab
Granules India packaging facility in US successfully completes USFDA inspectionJubilant Ingrevia receives USFDA EIR for Baruch facility
Lupin Receives USFDA EIR with VAI Status for Goa Manufacturing PlantLupin bags USFDA tentative nod for Olopatadine Hydrochloride Ophthalmic Solution(OTC)
Palamur Biosciences Faces USFDA Warning for Multiple GLP Compliance FailuresUSFDA issues complete response letter for Patritumab Deruxtecan in EGFR-Mutated NSCLC: Merck,...
Zydus Gets USFDA Approval for Generic Evoxac (Cevimeline) CapsulesZydus Life science's anticancer drug Pertuzumab Gets CDSCO Panel Nod for Additional Indication of...
Merck KGaA in late-stage talks to acquire SpringWorks for USD 3.5 billionMerck discontinues Phase 3 trial of Xevinapant in locally advanced head and neck cancer
X